Barclays’s Dermata Therapeutics DRMA Stock Holding History

Barclays’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-270	Closed	-$348	–	5476
2026 Q2	$348	Buy	+270	New	+$340	﹤0.01%	5051
2026 Q1	–	Sell	-2,402	Closed	-$5.57K	–	5141
2025 Q4	$5.57K	Buy	+2,402	New	+$7.85K	﹤0.01%	4979

Other funds holding DRMA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.34B AUM 13.98% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Highline Wealth Partners Sherman Oaks, California $527M AUM 13.86% 1-Year Est. Return

Barclays's DRMA Position: Q3 2026 in Review

Barclays sold out of Dermata Therapeutics (DRMA) in Q3 2026, closing a stake of 270 shares — an estimated $348 sold.

Barclays first reported a position in DRMA in Q4 2025 and held it in 2 quarters. The position peaked at $5.57K in Q4 2025. 5 funds tracked by Wall St. Rank hold DRMA as of Q3 2026.

Barclays reported no remaining Dermata Therapeutics position as of Q3 2026 after selling out during the quarter.
Barclays sold 270 Dermata Therapeutics shares in Q3 2026, an estimated $348.
Barclays first reported a position in Dermata Therapeutics in Q4 2025 and held it in 2 quarters.
Barclays's Dermata Therapeutics position peaked at $5.57K in Q4 2025.
5 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.